Yale Image Finder

Search the actual image content of 1,538,051 (and growing!) Open Access images and figures from PubMed Central.


Advanced...

Related Figures


Figure 2 Ultrasonographic images of a natural cyc...

Figure 1 Treatment schema.Italicized numbers repr...

Fig. 1 The Hangul typing practice and test prot...

Figure 3 Changes in quality of life from baseline...

Figure 5 Vaginal smear of the rats on four-day es...

Figure 1 Proportion of recurrence according to da...

Figure 6 Distribution of the length, in days, of ...

Figure 11 Estrous cycle parameters.A: Females' est...

Figure 1: Pegfilgrastin serum concentration in 34 ...

Figure 1 Geometric mean telatinib plasma concentr...

Figure 1: Treatment schedules. (A) Cisplatin/fluorouracil: four cycles of 4 days. (B) FOLFOX4: six cycles of 2 days.

Image Text (High Precision): radiotherapy weeks

Other Images from "Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer":


Figure 1 Treatment schedules. (A) Cisplatin/fluor...

Figure 2 CONSORT diagram. *One patient had hepati...

Figure 3 Overall survival (ITT population).

[Full Text] [PDF]

Abstract

Background:Concurrent chemoradiotherapy is a valuable treatment option for localised oesophageal cancer (EC), but improvement is still needed. A randomised phase II trial was initiated to assess the feasibility and efficacy in terms of the endoscopic complete response rate (ECRR) of radiotherapy with oxaliplatin, leucovorin and fluorouracil (FOLFOX4) or cisplatin/fluorouracil.Methods:Patients with unresectable EC (any T, any N, M0 or M1a), or medically unfit for surgery, were randomly assigned to receive either six cycles (three concomitant and three post-radiotherapy) of FOLFOX4 (arm A) or four cycles (two concomitant and two post-radiotherapy) of cisplatin/fluorouracil (arm B) along with radiotherapy 50 Gy in both arms. Responses were reviewed by independent experts.Results:A total of 97 patients were randomised (arm A/B, 53/44) and 95 were assessable. The majority had squamous cell carcinoma (82% arm A/B, 42/38). Chemoradiotherapy was completed in 74 and 66%. The ECRR was 45 and 29% in arms A and B, respectively. Median times to progression were 15.2 and 9.2 months and the median overall survival was 22.7 and 15.1 months in arms A and B, respectively.Conclusion:Chemoradiotherapy with FOLFOX4, a well-tolerated and convenient combination with promising efficacy, is now being tested in a phase III trial.


Search: Image Text (High Recall) Image Text (High Precision) Caption Abstract Title Full Text

All images and content copyright their respective owners. All else copyright ©2007-2008, Krauthammer Lab, Yale University.

Sign up for Yale Image Finder announcements:

Email: